Nuovi farmaci a bersaglio molecolare nei tumori neuroendocrini gastroenteropancreatici

Ito T, Lee L, Jensen RT (2016) Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother 17(16):2191–2205

Öberg K, Lamberts SW (2016) Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 23(12):R551–566

Lee MS, O’Neil BH (2016) Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol 7(5):804–818

Broder MS, Beenhouwer D, Strosberg JR et al. (2015) Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol 21(6):1945

Veenstra MJ, van Koetsveld PM, Dogan F et al (2016) Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. Available from http://www.oncotarget.com/abstract/9462

Alonso-Gordoa T, Capdevila J, Grande E (2015) GEP-NETs update: biotherapy for neuroendocrine tumours. Eur J Endocrinol 172(1):R31–46

Pópulo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13(2):1886–1918

Fazio N (2015) Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: a difficult conversion from biology to the clinic. World J Clin Oncol 6(6):194–197

Manfredi GI, Dicitore A, Gaudenzi G et al. (2015) PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine 48(2):363–370

Hobday TJ, Qin R, Reidy-Lagunes D et al. (2015) Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol 33(14):1551–1556

Raymond E, Hobday T, Castellano D et al. (2011) Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 30(S1):19–26

Abdel-Rahman O (2014) Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol 35(11):10615–10625